bionaturis

“Delegate and let democratize knowledge”

Applying the principles of effective delegation and let spread the knowledge over the whole organization are the base of the fourth point of the Decalogue of the executive role written by Juan José Almagro, president of Bionaturis.

Almagro, recently named deputy President of UNICEF Spain, is a lawyer, PhD in Work Sciences, columnist and writer. After a long and successful professional career in the multinational MAPFRE, he has become an icon of the corporate social responsibility and a reference thinker in the sector. He has been the president of the Boards of Directors at Bionaturis since July 2011.

Bionaturis will attend Bio international Convention, in San Diego (June 23-26)

During June 23-26, Bionaturis will take part in one of the most important bio meeting in the world: Bio International Convention, that is celebrated this year in San Diego (USA). The company, a reference in producing biological vaccines,  will be in this congress along with BBD Biophenix, company recently acquired by Bionaturis as part as its expansion business plan.

As Exhibitor, the company will participate at the Exhibitor Partnering event, where professionals and biotechnological institutions all over the world are more than welcome to meet our delegates. In 2013 edition, more than 5,000 business meetings were celebrated in this forum.

If you want to arrange a meeting with Bionaturis´ delegates at Bio International Convention, you can do it in advance emailing to info@bionaturis.com

For further information about Bio International Convention, please click http://convention.bio.org/

 

Bionaturis acquires BBD BIOPHENIX S.L.

Bionaturis (ticker BNT-MAB), an international reference company developing biological drugs, has just acquired the San Sebastian-based company BBD BIOPHENIX S.L (BBD), a leader in state-of-the-art screening systems for drug discovery. With this acquisition Bionaturis incorporates cutting-edge biotech assets to its organic growth, in this case, related to the use of zebra fish models for early determination of drug pharmacological profiles.

BBD is an international leader in the field of using the zebra fish model for drug toxicity and efficacy tests applying the latest technologies such as image analysis and automation. This alternative model improves the cost/effectiveness of preclinical phase for pharmaceutical, biotechnology, petrochemical, agrochemical, and cosmetic companies. BBD has a wide portfolio of big pharma clients, from United States and Europe.

About the acquisition, Victor Infante –Bionaturis´ CEO- states: “This acquisition is important to the growth of Bionaturis, improving its services and clients portfolio at international level, but above all, it means to add talent on board. The intrinsic talent of BBD is a reference of leadership and result-achievement”.

Arantza Muriana, R & D Director and founding partner of BBD BioPhenix comments on the operation: “It will help us meet the goals of market diversification and international expansion marked by the company”. She also highlights the important synergies between the two companies.

 

Strategic value

It´s a strategic acquisition for Bionaturis to support its growth and international expansion, at the time that contributes to its vision of facilitating industry the drug development process. With this operation, Bionaturis extends its international presence and multinational customers portfolio. For BBD, which will keep its headquarters in San Sebastian, it also represents a great opportunity for the fulfillment of its expansion and diversification plan.

 

About BBD BIOPHENIX

BBD BioPhenix is a Contract Research Organization (CRO) that […]

May Newsletter

If you want to know Bionaturis’ latest news, here you are our May Newsletter

IN THIS ISSUE

Bionaturis fulfilled its 3 million € increase of capital with oversubscription
Bionaturis 2013 annual report
“Educate yourself and help introduce collective learning processes”

Let’s get to know…

Elena de la Torre Madrid, 34 years old, born in Madrid. PhD in Biochemistry at Universidad Autónoma and Master in Biotechnology Management.
 

-When you were a child, what did you want to be as an adult?
A doctor.
-What do you like the most about your job?
Being part of something that has effect in society, knowing that we can improve something.
-What are your future challenges?
Keep on training in order to overcome my weeknesses.
-Your favourite dish
Paella (cooked by my father).
-A place
Paris.
-A film
‘The Silence of the Lambs’, by Jonathan Demme.
-A historical figure
The Apostle Paul.
-A book
‘The Lord of the Rings’, by Tolkien.
-A song
‘Nessun Dorma’, from the opera ‘Turandot’.
-What do you usually do in your free time?
Reading, cooking, walking, watching series…
-A proposal to get rid of the crisis
Reducing unnecessary expenses of public administrations: advisors, official cars and trips, controlling politicians´incomes, etc.., while investing more and more in R&D instead.
-How do you imagine the world in 20 years?
I can imagine it worse and worse. Social demands are making us more independents, selfish and leisure-seekers. I´ll do my best to change it at least as far as I could.

  Elena has been working as Project Manager at Bionaturis since April 2014.

Bionaturis fulfilled its 3 million € increase of capital with oversubscription

Bionaturis (BNT-MAB), an international reference company developing biological vaccines, has managed to raise 3.088.687 €, 100% of the recent increase of capital offer. It´s noteworthy that there has been an oversubscription of 76% of the total new issued shares. As a result, 441.241 new […]

Bionaturis will attend Biospain 2014

Biospain 2014 international meeting to be hold in the beautiful city of Santiago de Compostela will gather professionals and reference companies of the Biotechnology sector. Bionaturis, specialized in developing and producing biological vaccines has already confirmed its attendance to this important forum next September.

Biospain, organized by Asebio, is hold every two years and it claimed itself as the largest biotech event organized by a national bioindustry association in Europe and one of the largest in the world by the number of one-to-one meetings (2.775) and participating companies (762). The meeting will include a trade fair, a partnering event, an investment forum, plenary sessions about business trends, and scientific lectures.  BioSpain 2014 will make the most this special year named the “Year of Biotechnology” by the Spanish government.

Bionaturis´representatives would be more than happy to meet you at Biospain 2014!

For further information about the event

http://www.biospain2014.org/

You can arrange a meeting with Bionaturis´representatives by the official partnering system tool of the event or send us a request to info@bionaturis.com, subjecting “BioSpain 2014 meeting”. Thank you!

You can also visit us at booth B9 during the trade fair.

Bionaturis takes part in the MedCap Forum

As previous years Bionaturis (ticker BNT) will take part in the Medium Capitalization Companies Forum, organized by Bolsas y Mercados Españoles (BME) that celebrates on 27 and 28 May its tenth edition. This meeting has the aim of  fostering the liquidity and financial standing of these companies that are listed on Spanish Stock Markets.

Our CEO, Víctor Infante, will represent Bionaturis at the  private meetings  with investors that will take place in the Palacio de la Bolsa (Madrid). Infante has stated: “Meetings like these are very useful to keep a direct contact with our current and future investors, and other companies listed on financial markets as well. It´s a good opportunity for the MAB to show off its outstanding progression”.

Besides Bionaturis, the MAB will be represented by other top-perform companies such as Carbures and Gowex, among others.

For further information, please click here

“Educate yourself and help introduce collective learning processes”

The eager of a continuous training not only for managers but also for employees is the key of the third point of the Decalogue about the executive role written by Juan José Almagro, president of Bionaturis.

Almagro, recently named deputy President of UNICEF Spain, is a lawyer, PhD in Work Sciences, columnist and writer. After a long and successful professional career in the multinational MAPFRE, he has become an icon of the corporate social responsibility and a reference thinker in the sector. He has been the president of the Boards of Directors at Bionaturis since July 2011.

Bionaturis 2013 annual report

Bionaturis (BNT-MAB), an international reference company developing biological drugs, has released the 2013 Annual Report.

Victor Infante, Bionaturis’ CEO, has commented about the results: “The important point here is that our performance supports our strategy. Now the focus is on the internationalization process and to achieve the milestones needed to move forward our BNT programs to the market. We are on the right track. We keep estimations to increase our revenues around 400% this year”.

The 2013 annual report goes over the main milestones achieved during 2013 and the outlook for 2014 and beyond.

Key figures

Revenue for 2013 was €1.75 million as compared to €1.4 million for 2012, an increase of €0.35 million, or 25%. Net sales for 2013 was €0.89 million as compared to €0.44 million for 2012, an increase of 96%.

In 2013 EBITDA was €721 thousand as compared to €-246 thousand for 2012, an increase of €+ 967 thousand. In 2013 Net Result was €473 thousand as compared to €-342 thousand for 2012, an increase of €815 thousand.

Click here to get the full report

Bionaturis’ new shares will start quoting at April 30

The Spanish Alternative Stock Market (MAB, in Spanish) has informed about the starting of quotation of Bionaturis’ new issued shares as a result of the just-finished capital increase.

441.241 new shares will be trading in a record time since the ending of the capital increase last April 24. The operation was fulfilled with an oversubscription of 76%.

For further information, please click here  

Bionaturis fulfilled its 3 million € increase of capital with oversubscription

Bionaturis (BNT-MAB), an international reference company developing biological vaccines, has managed to raise 3.088.687 €, 100% of the recent increase of capital offer. It´s noteworthy that there has been an oversubscription of 76% of the total new issued shares. As a result, 441.241 new shares of a nominal value of 0.05 € each, plus an issue premium of 6.95 € have been subscribed.

It´s important to note that 74% of the final subscription has been issued by old shareholders.

After completing the process, Victor Infante, Bionaturis CEO has stated “from start to finish the whole process has surpassed our expectations. Oversubscription of 76%, the confident of old shareholders and the great potential of the new ones, even the negotiation during the pre-emptive subscription rights in the MAB have been overwhelming. On behalf of all the team we just want to say thank you for trusting in Bionaturis. This proof of confidence encourages us to implement successfully our expansion plan. We will release good news in this sense shortly.”

Purpose of the capital increase

The purpose of the capital increase is to finance the company´s internationalization plan and to undertake further investments.

 

April 24th, 2014|Press english|0 Comments|

Uso de cookies

Este sitio web utiliza cookies para que usted tenga la mejor experiencia de usuario. Si continúa navegando está dando su consentimiento para la aceptación de las mencionadas cookies y la aceptación de nuestra política de cookies, pinche el enlace para mayor información.

CERRAR